Eupraxia Pharmaceuticals Inc (EPRX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 63 | 55 | 46 | 55 | 38 |
| Accounts receivable | -7 | 113 | -9 | -183 | 50 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 871 | N/A |
| Other Working Capital | 1,701 | -1,476 | -707 | 569 | -4,739 |
| Other Operating Activity | -6,263 | -7,008 | -5,333 | -7,284 | -5,539 |
| Operating Cash Flow | $-4,507 | $-8,315 | $-6,003 | $-5,972 | $-10,190 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -60 | -166 | -169 | -44 | -42 |
| Investing Cash Flow | $-60 | $-166 | $-169 | $-44 | $-42 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 0 | 0 | 0 | 0 | -4,539 |
| Common Stock Issued | 73,891 | 0 | 0 | 31,705 | 0 |
| Other Financing Activity | 7 | 240 | 430 | 26 | -63 |
| Financing Cash Flow | $73,898 | $240 | $430 | $31,731 | $-4,601 |
| Exchange Rate Effect | -137 | 553 | 95 | -1,275 | 179 |
| Beginning Cash Position | 19,766 | 27,455 | 33,101 | 8,662 | 23,316 |
| End Cash Position | 88,959 | 19,766 | 27,455 | 33,101 | 8,662 |
| Net Cash Flow | $69,331 | $-8,242 | $-5,742 | $25,715 | $-14,833 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,507 | -8,315 | -6,003 | -5,972 | -10,190 |
| Capital Expenditure | -60 | -166 | -169 | -44 | -42 |
| Free Cash Flow | -4,567 | -8,481 | -6,172 | -6,017 | -10,232 |